Skip to main content

Health condition · Clinically reviewed

Genetic hearing loss, from newborn screening to gene panels and cochlear implants.

Around half of congenital hearing loss is genetic. Modern UK care picks it up early, names the gene where it can, and turns a diagnosis into a lifelong plan.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NHS Newborn Hearing Screening Programme, BSA, ENT UK and NHS England Genomic Medicine Service standards.

  • 03

    Current for 2026

    Reflects modern UK practice including comprehensive gene panels, bilateral cochlear implantation and emerging AAV OTOF gene therapy trials.

Key facts

Genetic hearing loss at a glance.

The essentials, in plain English: how common it is, the main types, and what the UK offers families today.

  • What it is

    Hearing loss caused by variants in genes essential to inner-ear development or function - accounts for around half of all congenital hearing loss and up to 60 per cent of childhood-onset cases.

  • Non-syndromic

    Around 70 per cent of genetic hearing loss - hearing only. GJB2 (connexin 26, DFNB1) is the single most common cause worldwide.

  • Syndromic

    Around 30 per cent - hearing loss plus other features. Usher, Pendred, Waardenburg, Alport, Jervell and Lange-Nielsen, BOR and Stickler are the classics.

  • Inheritance

    Autosomal recessive, autosomal dominant, X-linked and mitochondrial (including m.1555A>G aminoglycoside sensitivity).

  • How it is found

    The NHS Newborn Hearing Screening Programme uses OAE then AABR to flag babies for specialist paediatric audiology within weeks of birth.

  • What can be done

    Hearing aids, bilateral cochlear implants, bone-conduction devices, specialist deaf education, family genetic counselling and, for select genes, emerging gene therapy trials.

Why this guide matters

An early diagnosis changes the whole story.

Genetic hearing loss is common, treatable and increasingly nameable. The three points below shape everything else on this page.

  • Screening finds it early

    The NHS Newborn Hearing Screening Programme catches most congenital cases in the first weeks of life - and that head start is priceless for language.

  • Naming the gene guides care

    A gene panel result changes prognosis, recurrence risk and, in some cases, opens a trial pathway - it is more than a label.

  • Cochlear implants are transformative

    For severe to profound loss, bilateral cochlear implantation is now standard in the UK, with strong long-term outcomes.

How the diagnosis is made

From screening to a named gene and a plan.

The steps a UK paediatric audiology, ENT and genetics team will normally follow, in order.

  1. 01

    Assessing

    Newborn hearing screening

    The NHS NHSP uses otoacoustic emissions (OAE) with automated auditory brainstem response (AABR) to flag babies for further testing within the first weeks of life.

  2. 02

    Assessing

    Specialist paediatric audiology

    Diagnostic ABR, tympanometry and age-appropriate behavioural testing confirm the type, side and severity of hearing loss.

  3. 03

    Assessing

    Family and pregnancy history

    A careful three-generation family history plus questions about pregnancy, prematurity and neonatal aminoglycoside exposure guides the genetic workup.

  4. 04

    Confirming

    Genetic counselling and testing

    Specialist counselling followed by GJB2 testing and, when indicated, a comprehensive hearing loss gene panel or whole exome or genome sequencing through NHS England Genomic Medicine Service (specialist commissioned).

  5. 05

    Confirming

    Imaging - MRI IAM and brainstem

    MRI of the internal auditory meatus and brainstem checks cochlear anatomy, the vestibulocochlear nerve and features such as an enlarged vestibular aqueduct.

  6. 06

    Confirming

    Syndrome-directed workup

    Perchlorate discharge test and thyroid review for Pendred, ophthalmology and electroretinography for Usher and Stickler, urinalysis and renal review for Alport, and ECG for Jervell and Lange-Nielsen.

  7. 07

    Planning

    MDT plan and family cascade

    A specialist multidisciplinary meeting sets amplification, implantation, education and cascade testing plans for parents and siblings.

Typical timeline: from newborn screening referral to MDT plan within weeks in a specialist paediatric audiology service.

Symptoms

What genetic hearing loss looks like.

Congenital, progressive or adult-onset - and sometimes bundled with vision, thyroid, cardiac or renal features that point to a specific syndrome.

  • Congenital hearing loss

    Present from birth and picked up on newborn screening - often bilateral and sensorineural.

  • Progressive hearing loss

    Hearing that worsens through childhood or adulthood, for example with enlarged vestibular aqueduct or Alport syndrome.

  • Delayed speech and language

    Late babbling, limited vocabulary or unclear speech can be the first parental clue when screening is missed.

  • Vestibular symptoms

    Balance delay in infancy or later dizziness and unsteadiness, classic in Usher type 1 and some non-syndromic causes.

  • Tinnitus and hyperacusis

    Persistent ringing or discomfort with everyday sound, especially as hearing changes in adolescence and adulthood.

  • Syndromic features

    Vision change (Usher, Stickler), goitre (Pendred), pigmentary changes (Waardenburg), renal or ocular findings (Alport).

  • Adult-onset genetic loss

    Some autosomal dominant forms declare themselves in the twenties, thirties or later - a strong family history is the giveaway.

  • Red flag - sudden drop after antibiotic

    Rapid hearing loss after aminoglycoside exposure suggests m.1555A>G mitochondrial variant and needs urgent specialist review.

Treatment

How genetic hearing loss is managed in the UK.

Hearing aids, cochlear implants and specialist deaf education for most - with genetic counselling, syndrome-specific care and, for a few, gene therapy trials.

  • Hearing aids

    Specialist paediatric audiology-led fitting and verification - the first line for most degrees of loss and specialist commissioned.

  • Cochlear implant

    Bilateral implantation is increasingly standard for severe to profound loss, with early implantation transforming spoken-language outcomes. See our cochlear implant clinic guide.

  • Bone-conduction and BAHA

    Bone-anchored and other bone-conduction devices for conductive or mixed loss and for atretic ears - specialist assessed and specialist commissioned.

  • Auditory brainstem implant

    Selective option for children and adults without a usable auditory nerve, such as complete cochlear nerve aplasia - highly specialist commissioned.

  • Specialist SLT and deaf education

    Speech and language therapy, Teachers of the Deaf and access to BSL where families choose it - specialist commissioned support from the earliest months.

  • Family genetic counselling

    Cascade testing, recurrence-risk counselling, prenatal testing and preimplantation genetic diagnosis where families wish - specialist commissioned through Genomic Medicine.

  • Managing associated conditions

    Retinitis pigmentosa care in Usher, thyroid follow-up in Pendred, cardiology and QT management in Jervell and Lange-Nielsen, and renal care in Alport.

  • Emerging gene therapy

    AAV-delivered OTOF gene therapy for OTOF-related deafness is now in clinical trials in the UK and internationally - specialist commissioned trial pathways only.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your audiologist, ENT surgeon or clinical geneticist knows your family and history and can tell you which parts apply to you. If in doubt, get seen.

  • NHS Newborn Hearing Screening Programme (NHSP). Operational guidance.

  • British Society of Audiology (BSA). Recommended procedures for paediatric audiological assessment.

  • ENT UK. Position papers on paediatric hearing loss and cochlear implantation.

  • NHS England Genomic Medicine Service. National Genomic Test Directory - hearing loss panels.

  • NICE. Cochlear implants for children and adults with severe to profound deafness (TA566).

Red flags

When hearing loss needs urgent attention.

Most hearing loss is managed calmly, over time. These are the situations that need a specialist opinion promptly - or, in some, urgent care.

  • Failed newborn screen

    A referral from newborn hearing screening should always trigger a prompt specialist paediatric audiology appointment - do not wait to see if it settles.

  • Sudden loss after aminoglycoside

    Rapid sensorineural loss after gentamicin or another aminoglycoside suggests m.1555A>G - urgent audiology and genetics review is needed for the patient and the family.

  • Hearing loss with fainting

    Deafness with syncope, especially exercise-related, raises Jervell and Lange-Nielsen syndrome - urgent ECG for long QT.

  • Hearing loss and vision change

    Night blindness or tunnel vision alongside hearing loss suggests Usher syndrome and needs prompt ophthalmology and genetics input.

  • Hearing loss and haematuria

    Blood or protein in the urine with sensorineural hearing loss points to Alport syndrome - refer to nephrology and genetics.

  • Progressive loss with head injury

    Stepwise drops in hearing after minor knocks fit enlarged vestibular aqueduct - counsel on contact sports and refer for imaging.

  • Meningitis exposure

    Any bacterial meningitis needs urgent post-recovery audiology to catch acquired loss early, when cochlear implantation windows are short.

  • Family history of childhood deafness

    A sibling, parent or cousin with childhood hearing loss deserves early genetic counselling even if screening was passed.

  • Delayed speech at 18 to 24 months

    A quiet toddler is a reason to re-check hearing, even after a normal newborn screen - late-onset genetic losses do exist.

Living with it

A lifelong condition, with a strong support network.

Four things that make the biggest difference for children and adults with genetic hearing loss - early action, family testing, communication choices and specialist support.

A quiet reminder

Deaf and hearing pathways sit alongside, not in opposition.

Families choose what fits - and can revisit that choice as a child grows. Good services support the whole picture.

  1. 01 Early

    Act on screening quickly

    The first weeks and months matter for language - keep audiology and MDT appointments and start amplification without delay.

  2. 02 Family

    Cascade care into the family

    Genetic counselling helps siblings, cousins and future pregnancies - and often explains a hearing story that spans generations.

  3. 03 Access

    Choose the communication mix that fits

    Spoken language, BSL, Sign Supported English, or a blend - families lead this decision, supported by specialist deaf education.

  4. 04 Support

    Lean on RNID and NDCS

    The Royal National Institute for Deaf People and National Deaf Children's Society offer information, advocacy and peer support - specialist patient support alongside NHS care.

Frequently asked

Everything we get asked about genetic hearing loss.

Quick answers on GJB2, syndromes, screening, cochlear implants and emerging gene therapy.

  • What is genetic hearing loss?

    Hearing loss caused by variants in one of many genes that build or run the inner ear. It accounts for around 50 per cent of congenital hearing loss and up to 60 per cent of childhood-onset cases. Around 70 per cent is non-syndromic (hearing only) and 30 per cent is syndromic, with GJB2 (connexin 26) the single most common non-syndromic gene.

  • How is it inherited?

    All the classical patterns exist - autosomal recessive (the majority, including DFNB1 caused by GJB2), autosomal dominant, X-linked and mitochondrial. Mitochondrial variants such as m.1555A>G and m.7445A>G can cause hearing loss on their own or after exposure to aminoglycoside antibiotics.

  • How is genetic hearing loss diagnosed in the UK?

    It usually starts with the NHS Newborn Hearing Screening Programme (OAE and AABR), with referral into specialist paediatric audiology for diagnostic ABR and imaging. Genetic counselling and testing follow through the NHS England Genomic Medicine Service - starting with GJB2 and moving to comprehensive gene panels or whole exome or whole genome sequencing where indicated. This is all specialist commissioned.

  • Which syndromes should I know about?

    Usher syndrome (hearing loss with retinitis pigmentosa and vestibular problems - see our guide on deafness in one ear for related pathways), Pendred syndrome (hearing loss with goitre and enlarged vestibular aqueduct - see enlarged vestibular aqueduct), Waardenburg (pigmentary changes), Alport (kidney and eye involvement), Jervell and Lange-Nielsen (long QT), branchio-oto-renal (BOR) and Stickler syndrome are the main ones covered by UK panels.

  • Can genetic hearing loss be treated?

    Yes - modern management is genuinely transformative. Options include specialist paediatric hearing aids, bilateral cochlear implantation, bone-conduction devices and BAHA, selective auditory brainstem implants, and specialist speech and language therapy and deaf education. Associated features (retinitis pigmentosa in Usher, thyroid in Pendred, long QT in Jervell, renal disease in Alport) are managed alongside.

  • Is gene therapy available?

    For most genes, not yet. AAV-delivered OTOF gene therapy for OTOF-related autosomal recessive deafness is now in early clinical trials in the UK and internationally, with encouraging results in young children. Access is through specialist commissioned trial pathways only, and families interested in trials should ask their genetics and cochlear implant team for a referral.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.